10 Swiss Biotech Startups to Watch in 2020
Swiss Biotech startups are considered among the most promising and innovative companies in the world. Big industry players have already acquired many Biotech startups and large transactions had a relevant impact on the entire Swiss ecosystem. Discover now 10 Swiss Biotech startups to watch in 2020.
The practice of medicine has changed dramatically over the past years and we all know that the healthcare systems are becoming more complex and more expensive. Much of that progress is likely to result from advances in personalized medicine. This new treatment paradigm aims to ensure that patients get the therapies best suited to their specific genetic conditions.Millions of patients worldwide continue to benefit from biotech therapeutics developed by startups that are discovering, developing, and delivering innovative medicines to treat illnesses. For example, Crispr Therapeutics (IPO), Redvax (acquired by Roche), Covagen (acquired by J&J) and Amal Therapeutics (acquired by Boehringer Ingelheim) can be considered among the most successful Swiss Biotech startups in the country. As startups in Switzerland continue to develop new medicines that address significant unmet needs, future innovations in healthcare research will bring exciting new advances to help millions of people worldwide.
What does the future of biotechnology look like?
These 10 Swiss biotech startups are creating technologies aimed at fighting the rise of rare pediatric diseases, developing resistance-breaking cancer therapies, and growing personalized skin in labs. Learn how these top startups are applying research in biotechnology to discover new drugs and treatments:
Do you belong to the best Swiss Biotech and Medtech startups? Apply now to the Venture Leaders Life Sciences investors roadshow to Boston!
Araris Biotech AG: Building tomorrow's antibody-drug conjugates (ADCs)
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. Araris' inno... Read more
CUTISS AG: Personalized skin
CUTISS grows human skin in the lab for patients that suffer from skin defects (e.g. burns). CUTISS bio-engineers individually customized human skin starting off from a very small piece of patient’s ... Read more
Elthera AG: Tailored cancer therapies
Elthera AG is developing antibodies against the novel target L1CAM, an adhesion molecule whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types ... Read more
Nagi Bioscience SA: Unlocking organism-on-chip testing for every lab.
At Nagi Bioscience we develop innovative laboratory equipment that allows replacing animal testing with assays conducted on micro-organisms. Achieve unprecedented levels of scalability and reproducibi... Read more
Resistell AG: Revolutionary alternative for antibiotic susceptibility test
Resistell is revolutionizing Antibiotic Susceptibility Testing (AST) with the world’s fastest platform. Our CE IVD-certified AST for bloodstream infections has been validated in two clinical studies w... Read more
Scailyte AG: Predictive biomarkers, fueling next-gen pharma pipelines.
Scailyte pioneers single-cell biomarker discovery as this technology enters clinical trials. Our proprietary computational platform creates high-value IP and clinical assets in autoimmunity and oncolo... Read more
TOLREMO therapeutics AG: Development of resistance-breaking cancer therapies
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism ... Read more
Versantis AG: Conquer liver diseases and saves lives
Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our proprietary scavenging liposomes techno... Read more
Volumina Medical SA: Dynamic biomaterials for reconstructive and plastic surgery
Volumina is a clinical stage medtech start-up, spin off of EPFL. We are active in the field of tissue engineering and develops Adipearl, an injectable biomaterial for the reconstruction of volumes o... Read more
Related articles
Terapet closes seed financing round to advance the development of its medical device
read more
The Swiss Biotech Association Awards Venture Kick and Venturelab and Reports Continued Sector Growth
read more
Swiss Biotech Numab Therapeutics raises CHF 22 million
read more
10 Swiss Medtech Startups to Watch in 2020
read more
10 Swiss Wearables Startups to Watch (and Wear!)
read more
TOP 100 - Meet the 5 Best Swiss Biotech Startups of 2019 Ranking
read more